SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Azenta Announces Investments to Expand GENEWIZ Gene Synthesis Capabilities

Azenta says an exclusive licensing agreement with Elegen and its acquisition of SynPlexity will advance GENEWIZ gene synthesis capabilities.

AZTA

Story updates

12:03:28 PM UTC
SquawkNews
Azenta acquired SynPlexity and entered into two agreements with Elegen on October 28, 2026, advancing separate efforts to expand its DNA synthesis capabilities. The Elegen license provides exclusive, royalty-free rights to specified gene synthesis technology for five years, with an option to pay $2…

Related stories